Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) Shares Purchased by Cambridge Investment Research Advisors Inc.

Cambridge Investment Research Advisors Inc. boosted its stake in Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) by 14.0% in the first quarter, according to the company in its most recent disclosure with the SEC. The firm owned 13,790 shares of the company’s stock after purchasing an additional 1,694 shares during the quarter. Cambridge Investment Research Advisors Inc.’s holdings in Amphastar Pharmaceuticals were worth $400,000 as of its most recent filing with the SEC.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of the business. Smartleaf Asset Management LLC increased its stake in shares of Amphastar Pharmaceuticals by 222.1% in the fourth quarter. Smartleaf Asset Management LLC now owns 715 shares of the company’s stock worth $26,000 after buying an additional 493 shares during the last quarter. Raymond James Financial Inc. purchased a new stake in Amphastar Pharmaceuticals during the fourth quarter valued at about $3,450,000. PNC Financial Services Group Inc. lifted its stake in Amphastar Pharmaceuticals by 90.1% during the fourth quarter. PNC Financial Services Group Inc. now owns 4,203 shares of the company’s stock valued at $156,000 after buying an additional 1,992 shares in the last quarter. Amundi increased its holdings in shares of Amphastar Pharmaceuticals by 193.0% in the 4th quarter. Amundi now owns 19,583 shares of the company’s stock valued at $717,000 after purchasing an additional 12,899 shares during the period. Finally, Wealthfront Advisers LLC acquired a new position in Amphastar Pharmaceuticals in the fourth quarter worth approximately $9,268,000. 65.09% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several equities research analysts have recently weighed in on AMPH shares. JPMorgan Chase & Co. reissued a “neutral” rating and issued a $30.00 price objective (down from $45.00) on shares of Amphastar Pharmaceuticals in a research report on Monday, May 12th. Piper Sandler reduced their target price on Amphastar Pharmaceuticals from $36.00 to $32.00 and set a “neutral” rating on the stock in a report on Friday, March 21st. Wells Fargo & Company cut their target price on Amphastar Pharmaceuticals from $40.00 to $35.00 and set an “overweight” rating on the stock in a research note on Thursday, May 8th. Finally, Needham & Company LLC reaffirmed a “hold” rating on shares of Amphastar Pharmaceuticals in a report on Thursday, April 10th. Four research analysts have rated the stock with a hold rating and one has issued a buy rating to the company’s stock. According to MarketBeat, Amphastar Pharmaceuticals presently has an average rating of “Hold” and an average price target of $32.33.

Amphastar Pharmaceuticals Price Performance

Shares of AMPH stock opened at $22.21 on Friday. Amphastar Pharmaceuticals, Inc. has a twelve month low of $22.20 and a twelve month high of $53.96. The business has a fifty day simple moving average of $24.59 and a 200 day simple moving average of $28.47. The company has a quick ratio of 2.02, a current ratio of 2.95 and a debt-to-equity ratio of 0.80. The company has a market cap of $1.05 billion, a P/E ratio of 8.05, a P/E/G ratio of 5.84 and a beta of 0.72.

Amphastar Pharmaceuticals Profile

Amphastar Pharmaceuticals, Inc, a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a nasal spray for the treatment of severe hypoglycemia; Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin, to prevent and treat deep vein thrombosis; REXTOVY and Naloxone for opioid overdose; Glucagon for injection emergency kit; and Cortrosyn, for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency.